Corporate Profile

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.


BIOFILMS are estimated to be responsible for 80% of all human and animal bacterial infections, costing billions of dollars each year. These higher order structures form matrixes that attach and grow on living or non-living surfaces and can become 1000x more resistant to antibiotics, antimicrobials, biocides, and disinfectants.
This resiliency contributes to numerous human and animal health related problems such as wound care infections, recurrent urinary tract infections, tooth decay, medical device associated and hospital-acquired infections, as well as foodborne bacterial infections.


Kane Biotech’s mission is to be a royalty based revenue company licensing its anti-biofilm technologies to global industry players, first in the companion pet animal health market followed by the human health market.


Kane Biotech is at a turning point, focused now on commercialization as opposed to just R & D. We’ve developed a 4 Step approach to our commercialization strategy through which we have successfully implemented our first market opportunity within the North American veterinary channel.

People working at a food factory

“In work described in Antimicrobial Agents and Chemotherapy and the Journal of Industrial Microbiology and Biotechnology, researchers at Kane Biotech made therapeutic and analytical progress against biofilms, a particularly intractable form of bacterial growth.”

– Drug Discovery


• Signed exclusive licensing and distribution agreement with Dechra Veterinary Products LLC for the North American veterinary market (March 5, 2017).

• Eleven new patents issued, another three imminent.


  • Periodontal disease is the #1 disease in dogs and cats. The overall pet healthcare industry in the U.S. is valued at an estimated $69 billion USD in 2017*
  • Kane Biotech launched innovative pet oral care products under the brand names bluestem™ oral care (pet specialty channel) and StrixNB® (vet channel)



  • Wound care products using the patented technology DispersinB® are in development. The global market for wound care is $17 billion USD (2016)**
  • Ear infections are one of the most common reasons dogs are taken to the vet. Products in development include otic (ear) drops to break up biofilm in dogs’ and cats’ ears
  • Alosera™ shampoo for dogs, cats and horses works against atopic dermatitis bacteria and fungi by attacking biofilms, thereby altering the environment they live in so they are relatively easy to kill in their free-floating state
  • Shampoos and skin care formulations for skin conditions such as chronic dandruff, seborrheic dermatitis, athletes foot and atopic dermatitis for humans are in development
  • Aledex® technology provides a broad-spectrum antibiofilm and antimicrobial activity in medical device coating applications. Excellent data demonstrates the product’s ability to inhibit numerous catheter associated pathogens, and protect against infections
  • KBI Hard Surface Disinfectant disrupts the biofilm environment where bacteria live on hard metal surfaces and assures the embedded bacteria are killed



People working at a food factory

(all amounts as of September 30, 2017)
**Markets and Markets.

Download a printable version of the Corporate Profile